Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001641172-25-005244
Filing Date
2025-04-17
Accepted
2025-04-17 16:31:13
Documents
3

Document Format Files

Seq Description Document Type Size
1 formdefa14a.htm DEFA14A 14382
2 proxy_001.jpg GRAPHIC 477963
3 proxy_002.jpg GRAPHIC 455651
  Complete submission text file 0001641172-25-005244.txt   1301516
Mailing Address 217 W. MAIN STREET SOMERVILLE NJ 08876
Business Address 217 W. MAIN STREET SOMERVILLE NJ 08876 908-370-5102
ZyVersa Therapeutics, Inc. (Filer) CIK: 0001859007 (see all company filings)

EIN.: 862685744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-41184 | Film No.: 25847763
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)